This site is intended for healthcare professionals

CHMP recommends approval of nintedanib in systemic sclerosis-associated interstitial lung disease.- Boehringer

Read time: 1 mins
Published:29th Feb 2020
Condition: Interstitial Lung Disease/ILD
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest